《新股》大行科工(02543.HK)孖展超購增至6,688倍 料膺新股超購王
折疊自行車公司大行科工(02543.HK)昨日(4日)中午截至招股,綜合市場數據,截至券商數據,累計借出孖展額達到近2,622億元,以公開發售部分最多集資約3,920.4萬元計,孖展超額認購逾6,688倍,預料將超越2018年4月上市、公開超購6,288倍的毛記葵涌(01716.HK),成為本港新股超購王。
港交所(00388.HK)8月4日實施優化首次公開招股(IPO)市場定價及公開市場規定,若發行人採用新機制,當公開認購部分超額認購100倍或以上時,回撥比例可增至最多35%。但發行人亦可預先選定分配至公開認購部分的一定比例,介乎於發售股份的10%至60%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.